A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: Sevasemten Dose 1
DRUG: Sevasemten Dose 2
DRUG: Sevasemten Dose 3
DRUG: Sevasemten Dose 4
DRUG: Sevasemten Dose 5
DRUG: Placebo

Sponsor

Edgewise Therapeutics, Inc.